ESMO 2024 | Engineering bacteria to enhance immunotherapy for cancer treatment

Jan Theys • 14 Sep 2024

ESMO 2024

General

Jan Theys, PhD, Maastricht University, Maastricht, Netherlands, comments on the potential of engineering bacteria to express genes that are toxic to cancer cells, activate pro-drugs, or modulate the immune system. By using these engineered bacteria in conjunction with immunotherapy, tumors can be transformed into environments more responsive to treatment. This approach has the potential to expand the benefits of immunotherapy, making it more effective for a broader range of cancer patients. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.